Compare MLKN & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLKN | NNNN |
|---|---|---|
| Founded | 1905 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 1994 | N/A |
| Metric | MLKN | NNNN |
|---|---|---|
| Price | $14.41 | $26.03 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 925.7K | 21.5K |
| Earning Date | 03-25-2026 | 04-28-2026 |
| Dividend Yield | ★ 5.17% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.98 | N/A |
| Revenue | ★ $3,669,900,000.00 | N/A |
| Revenue This Year | $6.90 | N/A |
| Revenue Next Year | $4.79 | N/A |
| P/E Ratio | ★ $14.81 | $446.57 |
| Revenue Growth | ★ 1.14 | N/A |
| 52 Week Low | $13.77 | $5.91 |
| 52 Week High | $23.18 | $55.65 |
| Indicator | MLKN | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 24.91 | 56.06 |
| Support Level | $13.77 | $19.53 |
| Resistance Level | $19.86 | $30.70 |
| Average True Range (ATR) | 0.74 | 2.10 |
| MACD | -0.39 | 0.54 |
| Stochastic Oscillator | 10.25 | 70.81 |
MillerKnoll Inc, formerly Herman Miller Inc researches, designs, manufactures, sells, and distributes interior furnishings across the globe. The Company has three reportable segments: Americas Contract, International Contract, and Global Retail. The company's products are sold through a variety of sources, including owned and independent contract furniture dealers, direct customer sales, owned and independent retailers, direct-mail catalogs, and the company's online stores. The independent retailer division generates the majority of the firm's overall sales.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.